Filtered By:
Procedure: Heart Transplant
Countries: Canada Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 16 results found since Jan 2013.

When does life end? New organ donation strategy fuels debate
On a chilly holiday Monday in January 2020, a medical milestone passed largely unnoticed. In a New York City operating room, surgeons gently removed the heart from a 43-year-old man who had died and shuttled it steps away to a patient in desperate need of a new one. More than 3500 people in the United States receive a new heart each year. But this case was different—the first of its kind in the country. “It took us 6 months to prepare,” says Nader Moazami, surgical head of heart transplantation at New York University (NYU) Langone Health, where the operation took place. The run-up included oversight from an ethi...
Source: ScienceNOW - May 11, 2023 Category: Science Source Type: news

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association.
c Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research Abstract Cannabis, or marijuana, has potential therapeutic and medicinal properties related to multiple compounds, particularly Δ-9-tetrahydrocannabinol and cannabidiol. Over the past 25 years, attitudes toward cannabis have evolved rapidly, with expanding legalization of medical and recreational use at the state level in the United States and recreational use nationally in Canada and Uruguay. As a res...
Source: Circulation - August 4, 2020 Category: Cardiology Authors: Page RL, Allen LA, Kloner RA, Carriker CR, Martel C, Morris AA, Piano MR, Rana JS, Saucedo JF, American Heart Association Clinical Pharmacology Committee and Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Bas Tags: Circulation Source Type: research

Status, Indications, and Use of Cardiac Replacement Therapy in the Era of Multimodal Mechanical Approaches to Circulatory Support: A Scoping Review
In conclusion, the Syncardia temporary TAH is a reasonable bridge-to-transplant option for selected patients with either biventricular failure or special anatomic conditions.RésuméLes auteurs décrivent l’utilisation, les indications et les résultats actuels du cœur artificiel total (CAT) temporaire Syncardia (Syncardia Systems, Tucson, AZ, États-Unis), le seul CAT actuellement approuvé comme stratégie de transition vers une transplantation au Canada, aux États-Unis et en Europe. Implanté chez plus de 1 700 patients dans le monde, le CAT temporaire Syncardia est la pompe la plus utilisée. À l’échelle mondia...
Source: Canadian Journal of Cardiology - February 7, 2020 Category: Cardiology Source Type: research

Status, Indications and Use of Cardiac Replacement Therapy in the Era of Multimodal Mechanical Approaches to Circulatory Support: A Scoping Review
In conclusion, the SynCardia temporary TAH is a reasonable bridge-to-transplant option for selected patients with either biventricular failure or special anatomical conditions.
Source: Canadian Journal of Cardiology - November 30, 2019 Category: Cardiology Source Type: research

Let Plants be Thy Medicine – You Are What You Eat
Credit: Busani Bafana/IPSBy Esther Ngumbi and Ifeanyi NsoforILLINOIS, United States / ABUJA, Oct 16 2019 (IPS) United Nations World Food Day is celebrated around the world on October 16 under the theme: “Our Actions ARE Our Future. Healthy Diets for a Zero Hunger World”. This theme is timely, especially, because across Africa and around the world, there has been a gradual rise in malnutrition and diet-related non communicable diseases, as highlighted in The Lancet study and a United Nations Report published earlier this year. While 45 percent of deaths in children are from nutrition-related causes, mainly malnu...
Source: IPS Inter Press Service - Health - October 16, 2019 Category: International Medicine & Public Health Authors: Esther Ngumbi and Ifeanyi Nsofor Tags: Food & Agriculture Global Headlines Health World Food Day Source Type: news

Ambient Conditions Prior to Tokyo 2020 Olympic and Paralympic Games: Considerations for Acclimation or Acclimatization Strategies
This study was supported by ZonMw (Project: Thermo Tokyo: Beat the heat), Netherlands Organisation for Scientific Research (NWO) (Project: Citius, Altius, Sanius), and Heatshield, under EU Horizon 2020 grant agreement No 668786. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments The authors thank Dr. Tatsuro Amano (Niigata University, Japan) for his assistance with translating the Japanese Meteorological Agency website. Footnotes ^ https://rdrr.io/g...
Source: Frontiers in Physiology - April 23, 2019 Category: Physiology Source Type: research

Invasive Hemodynamics and Rejection Rates in Patients With Cardiac Sarcoidosis After Heart Transplantation
ConclusionsPatients with CS have similar post-transplant hemodynamics as patients without CS, without evidence of right ventricular dysfunction or pulmonary hypertension. Neither significant rejection nor recurrence of sarcoid in the allograft was observed in this cohort of patients with CS. Survival is similar between patients with CS and those without CS. Heart transplant is a viable strategy in selected patients with CS with excellent outcomes.RésuméIntroductionLa transplantation cardiaque orthotopique (TCO) est de plus en plus utilisée lors d’insuffisance cardiaque terminale liée à une sarcoïdose cardiaque (SC)...
Source: Canadian Journal of Cardiology - July 24, 2018 Category: Cardiology Source Type: research

Medtronic ’s HVAD System Just Became Less Invasive
Medtronic has gained FDA approval for a less-invasive implant approach of its HVAD System, a left ventricular assist device (LVAD) for advanced heart failure patients. The Dublin-based company picked up the technology when it acquired HeartWare in 2016. The firm said the technology is the only LVAD approved in the U.S. for implant via thoracotomy, a small lateral, surgical incision between the patient's ribs on the left side of the chest. FDA approval for HVAD implantation via thoracotomy is based on data from the LATERAL prospective clinical trial, in which 144 patients, with end-stage heart failure who were eligible for ...
Source: MDDI - July 12, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news

A Review of the Use of Direct Oral Anticoagulant Use in Orthotopic Heart Transplantation Recipients
Over 60 years ago, the vitamin K antagonist (VKA) warfarin was approved and remained the only oral anticoagulation agent until recently [1]. Currently, within North America and Europe there are four DOACs available. Dabigatran, first approved in Europe and Canada in 2008, then in the United States of America in 2010, followed by rivaroxaban, apixaban, and most recently edoxaban. The introduction of direct oral anticoagulants (DOACs) has been a major advancement and these agents are the preferred to VKAs for many indications [2 –5], including stroke prevention in nonvalvular atrial fibrillation (NVAF), acute treatment and...
Source: Transplantation Reviews - April 16, 2018 Category: Transplant Surgery Authors: Rosaleen Boswell, Glen J. Pearson Tags: Review article Source Type: research

Invasive Hemodynamics and Rejection Rates in Patients with Cardiac Sarcoidosis After Heart Transplantation
Conclusions CS patients have similar post-transplant hemodynamics as non-CS patients, without evidence of RV dysfunction or pulmonary hypertension. No significant rejection nor recurrence of sarcoid in the allograft were observed in this cohort of patients with CS. Survival is similar between CS and non-CS patients. Heart transplant is a viable strategy in selected CS patients with excellent outcomes. Teaser Orthotopic heart transplant (OHT) is utilized for end-stage heart failure due to cardiac sarcoidosis (CS). There is a lack of data on long-term outcomes. We explored changes in hemodynamics, allograft rejection and sur...
Source: Canadian Journal of Cardiology - April 7, 2018 Category: Cardiology Source Type: research

Experience with the SynCardia total artificial heart in a Canadian centre.
CONCLUSION: The TAH provides an alternative with low incidence of neurologic events in extremely fragile and complex patients waiting for heart transplantation. Complex and unusual anatomic conditions explained the current use of TAH. PMID: 28930049 [PubMed - as supplied by publisher]
Source: Canadian Journal of Surgery - September 22, 2017 Category: Surgery Authors: Nguyen A, Pellerin M, Perrault LP, White M, Ducharme A, Racine N, Carrier M Tags: Can J Surg Source Type: research